Sequential Use of Romiplostim after Eltrombopag for Refractory Thrombocytopenia in Hydrocarbon-Induced Myelodysplasia
- 3 September 2021
- journal article
- research article
- Published by Georg Thieme Verlag KG in International Journal of Angiology
- Vol. 33 (04) , 318-321
Abstract
We describe the clinical course of a 65-year-old male patient who suffered from hydrocarbon-induced myelodysplasia and was successfully treated with the thrombopoietin receptor agonist (TPO-RA), romiplostim. Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis, cytopenias, and increased risk of leukemic transformation. Here, we present a clinical vignette of MDS-associated thrombocytopenia refractory to first-line drugs as well as the TPO-RA, eltrombopag. To date, romiplostim is an U.S. Food and Drug Administration (FDA)-approved drug for idiopathic thrombocytopenic purpura and thrombocytopenia secondary to liver disease. Of note, currently the FDA advises against its use in MDS based on previous long-term safety concerns. Since the therapeutic options for thrombocytopenia in MDS patients are sparse, repurposing and reassessing romiplostim in this setting have been the focus of recent studies. At the time of writing, no published double-blind randomized clinical trials have conducted a head-to-head comparison between romiplostim and eltrombopag in thrombocytopenic MDS patients. To the best of our knowledge, for a thrombocytopenic patient in the setting of MDS, this is the first documented report of refractory clinical response after a 2-year use of eltrombopag in which replacement of treatment with romiplostim resulted in sustained physiological counts of thrombocytes within four weeks. * These authors had equal contribution. Received: 27 August 2020 Accepted: 19 January 2021 Publication Date: 03 September 2021 (online) © 2021. International College of Angiology. This article is published by Thieme. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USAKeywords
This publication has 26 references indexed in Scilit:
- Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromesProceedings of the National Academy of Sciences, 2013
- Myelodysplastic Syndrome and Benzene Exposure Among Petroleum Workers: An International Pooled AnalysisJNCI: Journal of the National Cancer Institute, 2012
- Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterationsBlood, 2012
- A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopeniaBlood, 2011
- Cause of death in patients with lower‐risk myelodysplastic syndromeCancer, 2010
- Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring SystemCancer, 2008
- Novel Thrombopoietic AgentsDrugs, 2008
- The incidence and impact of thrombocytopenia in myelodysplastic syndromesCancer, 2007
- Myelodysplastic SyndromeAnnual Review of Medicine, 2005
- Benzene in Gasoline and Crude Oil: Occupational and Environmental ImplicationsAIHA Journal, 2002